Wockhardt Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The stock has now surged 21.47% over two days, powered by the US FDA's acceptance of its New Drug Application (NDA) for the breakthrough antibiotic Zaynich.

The approval marks a landmark moment as it is the first time an Indian pharmaceutical company has had an NDA for a completely new chemical entity accepted by the US regulator. Zaynich, built on a novel β-lactam enhancer mechanism, has also received Fast Track status for its potential to address urgent medical needs. With over a decade of research behind it, the drug has demonstrated strong efficacy against highly resistant Gram-negative pathogens and has already helped critically ill patients in India and the US through compassionate use. The acceptance reflects confidence in Wockhardt's scientific depth and its global-standard development program.

Wockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. The company posted a consolidated net profit of Rs 78 crore in Q2 FY26 compared with a net loss of Rs 22 crore a year earlier, while net sales declined 3.34% YoY to Rs 782 crore.

Powered by Capital Market - Live News

Wockhardt today announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. The NDA was originally filed on September 30, 2025, and its acceptance marks a transformative moment?not only for Wockhardt, but also for the entire Indian pharmaceutical industry. This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA.

Zaynich has been granted Fast Track designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review.

A novel ?-lactam enhancer mechanism based Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens?microbes responsible for prolonged hospitalizations and significant mortality worldwide. Its life-saving impact has already been demonstrated through compassionate use in critically ill patients in both India and the United States.

Over the past decade, Zaynich has become one of the most extensively studied antibiotics globally, reflecting a comprehensive, science-driven development program initiated by Wockhardt in 2011. The company has successfully navigated a demanding non-clinical, clinical and regulatory pathway.

Powered by Capital Market - Live News

Aegis Vopak Terminals Ltd, JM Financial Ltd, Star Health & Allied Insurance Company Ltd, KFin Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 01 December 2025.

Wockhardt Ltd notched up volume of 98.36 lakh shares by 14:14 IST on NSE, a 34.53 fold spurt over two-week average daily volume of 2.85 lakh shares. The stock rose 18.76% to Rs.1,466.70. Volumes stood at 4.46 lakh shares in the last session.

Aegis Vopak Terminals Ltd notched up volume of 50.21 lakh shares by 14:14 IST on NSE, a 16.58 fold spurt over two-week average daily volume of 3.03 lakh shares. The stock rose 5.53% to Rs.274.95. Volumes stood at 3.81 lakh shares in the last session.

JM Financial Ltd saw volume of 541.65 lakh shares by 14:14 IST on NSE, a 15.25 fold spurt over two-week average daily volume of 35.52 lakh shares. The stock increased 7.12% to Rs.155.70. Volumes stood at 25.34 lakh shares in the last session.

Star Health & Allied Insurance Company Ltd recorded volume of 19.02 lakh shares by 14:14 IST on NSE, a 6.54 times surge over two-week average daily volume of 2.91 lakh shares. The stock lost 1.01% to Rs.483.00. Volumes stood at 3.45 lakh shares in the last session.

KFin Technologies Ltd clocked volume of 25.95 lakh shares by 14:14 IST on NSE, a 4.32 times surge over two-week average daily volume of 6.01 lakh shares. The stock gained 3.66% to Rs.1,095.00. Volumes stood at 4.93 lakh shares in the last session.

Powered by Capital Market - Live News

The aforementioned NDA was filed on 30 September 2025.

This is the first time in history that an NDA for a new chemical entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,? the company said in a statement.

Zaynich has been granted ?fast track? designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review.

Zaynich, a β-lactam enhancer, has drawn international interest for its activity against resistant gram-negative bacteria, which are linked to long hospital stays and high mortality. It has been used in critically ill patients in India and the United States.

Wockhardt is a global pharmaceutical and biotechnology company focused on developing anti-infective solutions.

The company had reported a consolidated net profit of Rs 78 crore in Q2 FY26 as against a net loss of Rs 22 crore recorded in Q2 FY25. Net sales declined 3.34% to Rs 782 crore in Q2 FY26 as compared with Q2 FY25.

Powered by Capital Market - Live News